title: Can somatostatin antagonism prevent hypoglycaemia during exercise in type 1 diabetes?
abstract: The prevention and management of exercise-induced hypoglycaemia remains a challenge for patients with type 1 diabetes. Strategies involving changes to insulin dosing and/or carbohydrate consumption in anticipation of or during different types of exercise have proved to be helpful but not sufficient to fully prevent the hypoglycaemic risk. Meanwhile, the defect in glucagon secretion in response to hypoglycaemia in diabetes and the contributory role of somatostatin to this dysregulation constitute an important therapeutic target. In this issue of Diabetologia (DOI 10.1007/s00125-016-3953-0 ), Leclair et al show that selective somatostatin receptor 2 antagonists can enhance glucagon secretion in rats with streptozotocin-induced diabetes during exercise. The implications of their interesting findings are discussed, as well as limitations and potential for clinical applications, together with other glucagon-based options for tackling exercise-induced hypoglycaemia in diabetes.
authors.affiliation: Institut de recherches cliniques de Montréal, 110, avenue des Pins Ouest, Montréal, Québec, H2W 1R7, Canada.
authors.forename: Nadine
authors.initials: N
authors.lastname: Taleb
authors.affiliation: Institut de recherches cliniques de Montréal, 110, avenue des Pins Ouest, Montréal, Québec, H2W 1R7, Canada. Remi.rabasa-lhoret@ircm.qc.ca.|Nutrition Department, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada. Remi.rabasa-lhoret@ircm.qc.ca.
authors.forename: Rémi
authors.initials: R
authors.lastname: Rabasa-Lhoret
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D004195:Disease Models, Animal; D005934:Glucagon / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism; D007003:Hypoglycemia / Q000188:drug therapy* / Q000209:etiology*; D007328:Insulin / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010456:Peptides, Cyclic / Q000627:therapeutic use; D010805:Physical Conditioning, Animal / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors*
chemical_list: D001786:Blood Glucose; D007328:Insulin; C121568:PRL 2903; D010456:Peptides, Cyclic; D017481:Receptors, Somatostatin; D005934:Glucagon; C093733:somatostatin receptor 2; D005947:Glucose
keywords: Exercise; Glucagon; Hypoglycaemia; Somatostatin receptor type 2 antagonists; Type 1 diabetes